Gastric cancer (GC) is one of the deadliest malignancies worldwide. Complex disease
heterogeneity, late diagnosis, and suboptimal therapies result in the poor prognosis of …

The clinical utility of the chemotherapeutic agent cisplatin is restricted by cancer drug
resistance, which is either intrinsic to the tumor or acquired during therapy. Epigenetics is …

Acquired chemoresistance against doxorubicin remains an obstacle in long-term treatment.
The comprehensive molecular mechanism underlying the acquirement of doxorubicin …

Background Proline/arginine-rich end leucine-rich repeat protein (PRELP) is a member of
the small leucine-rich proteoglycan family of extracellular matrix proteins, which is markedly …

Despite continual efforts being made with multiple clinical studies and deploying cutting-
edge diagnostic tools and technologies, the discovery of new cancer therapies remains of …

Liver cancer is the sixth most commonly occurring cancer and costs millions of lives per
year. The diagnosis of hepatocellular carcinoma (HCC) has relied on scanning techniques …

Gastrointestinal (GI) malignancies account for substantial mortality and morbidity worldwide.
They are generally promoted by dysregulated signal transduction and epigenetic pathways …

Pancreatic cancer is the third leading cause of cancer-related death in the United States,
with a 5-year survival rate of only 12%. The poor prognosis of pancreatic cancer is primarily …

Purpose There has been an increase in the incidence of signet ring cell cancer (SRCC) of
the stomach and gastro-esophageal junction (GEJ). The multistage carcinogenesis involving …

Abstract Glioma accounts for 40–50% of craniocerebral tumors, whose outcome rarely
improves after standard treatment. The development of new therapeutic targets for glioma …